MedTrace Logo

Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

NCT05523648 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2022-08-31

No results posted yet for this study

Summary

The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of Ganshuang granules combined with tenofovir in the treatment of CHB complicated with NAFLD.

Conditions

Interventions

DRUG

Chronic Hepatitis B

92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.

Sponsors & Collaborators

  • Sichuan Leshan Traditional Chinese Medicine Hospital

    lead OTHER

Principal Investigators

  • Qin Yang, MM · Sichuan Leshan Traditional Chinese Medicine Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-05
Primary Completion
2021-12-20
Completion
2021-12-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523648 on ClinicalTrials.gov